BioCentury

7:00 AM GMT, Aug 6, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

CV chronicles

CV chronicles

CV chroniclesWith its shares down 62% since it launched angina drug Ranexa ranolazine in March 2006, CV Therapeutics last week asked biotech banker Fred Frank of Lehman to counsel the company on strategic alternatives. A big chunk of the valuation falloff came on March 6,

Read the full 468 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.